Lutatera IV infusion, from Novartis Pharma, contains Lutetium oxodotreotide (177Lu). This radioactive pharmaceutical is designed for specific therapeutic uses, typically targeting neuroendocrine tumors that express somatostatin receptors. It is supplied as 7.4GBq in 25mL per bottle, with YJ code 4291458A1020.
Lutatera IV infusion
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →